Treating Crohn's disease by inducing T lymphocyte apoptosis

Annals of the New York Academy of Sciences

Volumn 973, Issue , 2002, Pages 166-180

  Van Den Brande, Jan M H ^a   Peppelenbosch, Maikel P ^a   Van Deventer, Sander J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Crohn's disease (CD); Immunological homeostasis; T lymphocyte

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

APOPTOSIS; CELL DEATH; COMPARATIVE STUDY; CONFERENCE PAPER; CROHN DISEASE; DRUG EFFECT; HOMEOSTASIS; IMMUNOLOGY; INFLAMMATION; INTESTINE MUCOSA; LAMINA PROPRIA; NONHUMAN; PUBLICATION; T LYMPHOCYTE;

ANIMALIA;

EID: 0036962407     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04628.x     Document Type: Conference Paper

References (100)

1. HAMPE, J., A. CUTHBERT, P.J. CROUCHER, et al. 2001. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357: 1925-1928.
2. OGURA, Y., D.K. BONEN, N. INOHARA, et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606.
3. HUGOT, J.P., M. CHAMAILLARD, H. ZOUALI, et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603.
4. SANDLER, R.S. 1994. Epidemiology of inflammatory bowel disease. In Inflammatory Bowel Disease: From Bench to Bedside, pp. 5-31. Williams & Wilkins. Baltimore.
5. RUSSEL, M.G. & R.W. STOCKBRUGGER. 1996. Epidemiology of inflammatory bowel disease: an update. Scand. J. Gastroenterol. 31: 417-427.
6. HOMMES, D.W. & S.J. VAN DEVENTER. 2000. Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease. Curr. Opin. Clin. Nutr. Metab. Care 3: 191-195.
7. VAN DEVENTER, S.J. 1999. Anti-TNF antibody treatment of Crohn's disease. Ann. Rheum. Dis. 58(Suppl. 1): I114-I120.
8. GREEN, J.T., J. RHODES, K. RAGUNATH, et al. 1998. Clinical status of ulcerative colitis in patients who smoke. Am. J. Gastroenterol. 93: 1463-1467.
9. RUSSEL, M.G., F.H. NIEMAN, J.M. BERGERS & R.W. STOCKBRUGGER. 1996. Cigarette smoking and quality of life in patients with inflammatory bowel disease: South Limburg IBD Study Group. Eur. J. Gastroenterol. Hepatol. 8: 1075-1081.
10. WATANABE, M., H. TAKAISHI, Y. HOSODA, et al. 1995. CD4+ intestinal mucosal lymphocytes in the pathogenesis of Crohn's disease. J. Gastroenterol. 30(Suppl. 8): 73-75.
11. CUVELIER, C.A., J. QUATACKER, H. MIELANTS, et al. 1993. M cells are damaged and increased in number in inflamed human ileal mucosa. Eur. J. Morphol. 31: 87-91.
12. VAN DEVENTER, S.J. 1998. Cytokines and mucosal inflammatory response in Crohn's disease. Eur. J. Surg. 164: 897-901.
13. POWRIE, F. 1995. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 3: 171-174.
14. ELSON, C.O. 1997. Advances in mucosal immunity. Drugs 54: 13-14.
15. CHER, D.J. & T.R. MOSMANN. 1987. Two types of murine helper T cell clone: II. Delayed-type hypersensitivity is mediated by TH1 clones. J. Immunol. 138: 3688-3694.
16. BASS, H., T. MOSMANN & S. STROBER. 1989. Evidence for mouse Th1- and Th2-like helper T cells in vivo: selective reduction of Th1-like cells after total lymphoid irradiation. J. Exp. Med. 170: 1495-1511.
17. MONTELEONE, G., L. BIANCONE, R. MARASCO, et al. 1997. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112: 1169-1178.
18. HSIEH, C.S., S.E. MACATONIA, C.S. TRIPP, et al. 1993. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549.
19. HSIEH, C.S., A.B. HEIMBERGER, J.S. GOLD, et al. 1992. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc. Natl. Acad. Sci. USA 89: 6065-6069.
20. GROUX, H., A. O'GARRA, M. BIGLER, et al. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737-742.
21. POWRIE, F., J. CARLINO, M.W. LEACH, et al. 1996. A critical role for transforming growth factor-beta, but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J. Exp. Med. 183: 2669-2674.
22. PARRONCHI, P., P. ROMAGNANI, F. ANNUNZIATO, et al. 1997. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. J. Pathol. 150: 823-832.
23. FUSS, I.J., M. NEURATH, M. BOIRIVANT, et al. 1996. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157: 1261-1270.
24. KUHN, R., J. LOHLER, D. RENNICK, et al. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274.
25. RENNICK, D., N. DAVIDSON & D. BERG. 1995. Interleukin-10 gene knock-out mice: a model of chronic inflammation. Clin. Immunol. Immunopathol. 76: S174-S178.
26. BERG, D.J., N. DAVIDSON, R. KUHN, et al. 1996. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J. Clin. Invest. 98: 1010-1020.
27. high subset of CD4+ T cells. Am. J. Pathol. 148: 1503-1515.
28. POWRIE, F., R.L. COFFMAN & R. CORREA-OLIVEIRA. 1994. Transfer of CD4+ T cells to C.B-17 SCID mice: a model to study Th1 and Th2 cell differentiation and regulation in vivo. Res. Immunol. 145: 347-353.
29. VAN DEVENTER, S.J. 2001. Biological therapies of inflammatory bowel disease. Acta Gastroenterol. Belg. 64: 177-181.
30. FREITAS, A.A. & B.B. ROCHA. 1993. Lymphocyte life spans: homeostasis, selection, and competition. Immunol. Today 14: 25-29.
31. TANCHOT, C., M.M. ROSADO, F. AGENES, et al. 1997. Lymphocyte homeostasis. Semin. Immunol. 9: 331-337.
32. VAN PARIJS, L. & A.K. ABBAS. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280: 243-248.
33. LENSCHOW, D.J., T.L. WALUNAS & J.A. BLUESTONE. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14: 233-258.
34. BOISE, L.H., A.J. MINN, P.J. NOEL, et al. 1995. CD28 costimulation can promote T cell survival by enhancing the expression of Bc1-XL. Immunity 3: 87-98.
35. FOY, T.M., A. ARUFFO, J. BAJORATH, et al. 1996. Immune regulation by CD40 and its ligand GP39. Annu. Rev. Immunol. 14: 591-617.
36. SPRENT, J. & D.F. TOUGH. 1994. Lymphocyte life-span and memory. Science 265: 1395-1400.
37. VAN PARIJS, L. & A.K. ABBAS. 1996. Role of Fas-mediated cell death in the regulation of immune responses. Curr. Opin. Immunol. 8: 355-361.
38. KRUMMEL, M.F. & J.P. ALLISON. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183: 2533-2540.
39. 2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70. J. Exp. Med. 186: 1645-1653.
40. SADLACK, B., H. MERZ, H. SCHORLE, et al. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261.
41. WAHL, S.M. 1994. Transforming growth factor beta: the good, the bad, and the ugly. J. Exp. Med. 180: 1587-1590.
42. MOORE, K.W., A. O'GARRA, R. DE WAAL MALEFYT, et al. 1993. Interleukin-10. Annu. Rev. Immunol. 11: 165-190.
43. FISCHER, A. & B. MALISSEN. 1998. Natural and engineered disorders of lymphocyte development. Science 280: 237-243.
44. OHASHI, P.S., S. OEHEN, K. BUERKI, et al. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65: 305-317.
45. KRAMMER, P.H. 2000. CD95's deadly mission in the immune system. Nature 407: 789-795.
46. LEITHAUSER, F., J. DHEIN, G. MECHTERSHEIMER, et al. 1993. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69: 415-429.
47. KLAS, C., K.M. DEBATIN, R.R. JONKER & P.H. KRAMMER. 1993. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5: 625-630.
48. KRAMMER, P.H. 1999. CD95(APO-1/Fas)-mediated apoptosis: live and let die. Adv. Immunol. 71: 163-210.
49. MARIANI, S.M., B. MATIBA, C. BAUMLER & P.H. KRAMMER. 1995. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 25: 2303-2307.
50. TANAKA, M., T. SUDA, K. HAZE, et al. 1996. Fas ligand in human serum. Nat. Med. 2: 317-322.
51. TANAKA, M., T. SUDA, T. TAKAHASHI & S. NAGATA. 1995. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14: 1129-1135.
52. KISCHKEL, F.C., S. HELLBARDT, I. BEHRMANN, et al. 1995. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14: 5579-5588.
53. MUZIO, M., A.M. CHINNAIYAN, F.C. KISCHKEL, et al. 1996. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85: 817-827.
54. LENARDO, M., K.M. CHAN, F. HORNUNG, et al. 1999. Mature T lymphocyte apoptosis - Immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17: 221-253.
55. SCAFFIDI, C., S. FULDA, A. SRINIVASAN, et al. 1998. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17: 1675-1687.
56. LUO, X., I. BUDIHARDJO, H. ZOU, et al. 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490.
57. LI, H., H. ZHU, C.J. XU & J. YUAN. 1998. Cleavage of B1D by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501.
58. KROEMER, G. 1995. The pharmacology of T cell apoptosis. Adv. Immunol. 58: 211-296.
59. VERHAGEN, A.M., P.G. EKERT, M. PAKUSCH, et al. 2000. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102: 43-53.
60. DU, C., M. FANG, Y. LI, et al. 2000. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33-42.
61. CAIN, K., S.B. BRATTON, C. LANGLAIS, et al. 2000. Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes. J. Biol. Chem. 275: 6067-6070.
62. OGURA, Y., N. INOHARA, A. BENITO, et al. 2001. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J. Biol. Chem. 276: 4812-4818.
63. WYLLIE, A.H., J.F. KERR & A.R. CURRIE. 1980. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68: 251-306.
64. KABELITZ, D., T. POHL & K. PECHHOLD. 1993. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol. Today 14: 338-339.
65. AKBAR, A.N. & M. SALMON. 1997. Cellular environments and apoptosis: tissue microenvironments control activated T-cell death. Immunol. Today 18: 72-76.
66. BU, P., A. KESHAVARZIAN, D.D. STONE, et al. 2001. Apoptosis: one of the mechanisms that maintains unresponsiveness of the intestinal mucosal immune system. J. Immunol. 166: 6399-6403.
67. BOIRIVANT, M., R. PICA, R. DE MARIA, et al. 1996. Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. J. Clin. Invest. 98: 2616-2622.
68. DE MARIA, R., M. BOIRIVANT, M.G. CIFONE, et al. 1996. Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes: a potential role for the acidic sphingomyelinase pathway in normal immunoregulation. J. Clin. Invest. 97: 316-322.
69. ITOH, J., C. DE LA MOTTE, S.A. STRONG, et al. 2001. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 49: 35-41.
70. BOIRIVANT, M., M. MARINI, G. DI FELICE, et al. 1999. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 116: 557-565.
71. INA, K., J. ITOH, K. FUKUSHIMA, et al. 1999. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J. Immunol. 163: 1081-1090.
72. ATREYA, R., J. MUDTER, S. FINOTTO, et al. 2000. Blockade of interleukin 6 trans-signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6: 583-588.
73. FUSS, I.J., T. MARTH, M.F. NEURATH, et al. 1999. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 117: 1078-1088.
74. TEN HOVE, T., M.P. PEPPELENBOSCH & S.J.H. VAN DEVENTER. 2002. Infliximab treatment induces apoptosis of activated lamina propria T-lymphocytes in Crohn's disease. Gut 50: 206-211.
75. NEURATH, M., S. FINOTTO, I. FUSS, et al. 2001. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol. 22: 21-26.
76. MONTELEONE, G., T. PARRELLO, F. LUZZA & F. PALLONE. 1998. Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7. Gut 43: 620-628.
77. ARMANT, M., G. DELESPESSE & M. SARFATI. 1995. IL-2 and IL-7, but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression. Immunology 85: 331-337.
78. PALMER, E.M., L. FARROKH-SIAR, J. MAGUIRE VAN SEVENTER & G.A. VAN SEVENTER. 2001. IL-12 decreases activation-induced cell death in human naive Th cells costimulated by intercellular adhesion molecule-1: i. IL-12 alters caspase processing and inhibits enzyme function. J. Immunol. 167: 749-758.
79. GROSS, V., T. ANDUS, I. CAESAR, et al. 1992. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 102: 514-519.
80. MITSUYAMA, K., A. TOYONAGA, E. SASAKI, et al. 1995. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 36: 45-49.
81. KISHIMOTO, T., S. AKIRA & T. TAGA, 1992. Interleukin-6 and its receptor: a paradigm for cytokines. Science 258: 593-597.
82. YAMAMOTO, M., K. YOSHIZAKI, T. KISHIMOTO & H. ITO, 2000. IL-6 is required for the development of Th1 cell-mediated murine colitis. J. Immunol. 164: 4878-4882.
83. CATLETT-FALCONE, R., T.H. LANDOWSKI, M.M. OSHIRO, et al. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115.
84. FUKADA, T., M. HIBI, Y. YAMANAKA, et al. 1996. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 5: 449-460.
85. ARMSTRONG, A.M., K.R. GARDINER, S.J. KIRK, et al. 1997. Tumour necrosis factor and inflammatory bowel disease. Br. J. Surg. 84: 1051-1058.
86. VAN DEVENTER, S.J. 1997. Tumour necrosis factor and Crohn's disease. Gut 40: 443-448.
87. BREESE, E.J., C.A. MICHIE, S.W. NICHOLLS, et al. 1994. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106: 1455-1466.
88. BRAEGGER, C.P., S. NICHOLLS, S.H. MURCH, et al. 1992. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339: 89-91.
89. TARGAN, S.R., S.B. HANAUER, S.J. VAN DEVENTER, et al. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337: 1029-1035.
90. VAN DULLEMEN, H.M., S.J. VAN DEVENTER, D.W. HOMMES, et al. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135.
91. VAN DULLEMEN, H.M., G.J. WOLBINK, P.C. WEVER, et al. 1998. Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease: relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn's disease. Scand. J. Gastroenterol. 33: 1094-1098.
92. RUTGEERTS, P., S.J. VAN DEVENTER, et al. 1997. Retreatment with anti-TNF chimeric monoclonal antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Digestive Disease Week Abstract Book.
93. PRESENT, D.H., P. RUTGEERTS, S. TARGAN, et al. 1999. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340: 1398-1405.
94. TEN HOVE, T., C. VAN MONTFRANS, M.P. PEPPELENBOSCH & S.J. VAN DEVENTER. 2002. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50: 206-211.
95. SCALLON, B.J., M.A. MOORE, H. TRINH, et al. 1995. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7: 251-259.
96. ARNOTT, I.D., A. SHAND & S. GHOSH. 2000. Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4. Am. J. Gastroenterol. 95: 3326-3327.
97. DUDLEY, E., F. HORNUNG, L. ZHENG, et al. 1999. NF-kappaB regulates Fas/APO-1/CD95- and TCR-mediated apoptosis of T lymphocytes. Eur. J. Immunol. 29: 878-886.
98. LUGERING, A., M. SCHMIDT, N. LUGERING, et al. 2001. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121: 1145-1157.
99. WATTS, A.D., N.H. HUNT, Y. WANIGASEKARA, et al. 1999. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in "reverse signalling". EMBO J. 18: 2119-2126.
100. HARASHIMA, S., T. HORIUCHI, N. HATTA, et al. 2001. Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J. Immunol. 166: 130-136.